Skip to main content

Table 3 ODs and ED for (+)-[18F]flubatine based on human data

From: Radiation dosimetry of the α4β2 nicotinic receptor ligand (+)-[18F]flubatine, comparing preclinical PET/MRI and PET/CT to first-in-human PET/CT results

Target organ OD SD ED contribution SD
(mSv/MBq) (mSv/MBq)
Adrenals 1.30E−02 2.26E−03 1.12E−04 1.94E−05
Brain 2.86E−02 3.33E−03 2.86E−04 3.33E−05
Breasts 6.29E−03 3.86E−04 7.55E−04 4.63E−05
Gallbladder wall 2.34E−02 9.30E−03 2.01E−04 7.99E−05
LLI wall 1.67E−02 2.89E−03 1.00E−03 1.74E−04
Small intestine 2.94E−02 8.90E−03 2.53E−04 7.66E−05
Stomach wall 2.04E−02 3.89E−03 2.44E−03 4.67E−04
ULI wall 3.24E−02 1.02E−02 1.94E−03 6.14E−04
Heart wall 1.57E−02 1.65E−03 1.35E−04 1.42E−05
Kidneys 3.81E−02 4.52E−03 3.28E−04 3.89E−05
Liver 5.31E−02 2.98E−02 2.12E−03 1.19E−03
Lungs 2.70E−02 2.60E−03 3.24E−03 3.12E−04
Muscle 7.90E−03 1.26E−04 6.80E−05 1.08E−06
Ovaries 1.31E−02 1.22E−03 1.05E−03 9.73E−05
Pancreas 2.08E−02 4.11E−03 1.79E−04 3.53E−05
Red marrow 1.49E−02 8.50E−04 1.79E−03 1.02E−04
Osteogenic cells 1.42E−02 7.81E−04 1.42E−04 7.81E−06
Skin 5.52E−03 1.27E−04 5.52E−05 1.27E−06
Spleen 1.34E−02 4.19E−03 1.15E−04 3.60E−05
Testes 2.17E−02 1.21E−02 1.53E−03 1.33E−03
Thymus 7.48E−03 2.91E−04 6.43E−05 2.50E−06
Thyroid 2.29E−02 4.37E−03 9.17E−04 1.75E−04
Urinary bladder wall 1.02E−01 2.96E−02 4.09E−03 1.18E−03
Uterus 1.55E−02 1.71E−03 1.33E−04 1.47E−05
Total body 1.05E−02 8.42E−04
ED (mSv/MBq)    2.30E−02 1.91E−03
ED (mSv/MBq) ICRP 60   2.48E−02 1.18E−03
  1. ODs calculated for the adult male model (73.7 kg, implemented in OLINDA)
  2. OD organ dose, ED effective dose (ICRP 103), SD standard deviation mean over three human subjects